ABSTRACT

Pharmacogenomics plays a crucial role in understanding the interindividual variation in drug response and identifying genetic factors that affect drug reactions. In the context of cardiovascular drugs, which are commonly used to treat cardiovascular diseases, pharmacogenomics has the potential to optimize drug efficacy and minimize the risk of adverse reactions. Personalized medicine, which integrates genetic and genomic data with clinical and environmental factors, enables the identification of patients at risk for ADRs and the development of individualized treatment approaches. Pharmacogenomic studies have demonstrated positive results for many cardiovascular drugs, indicating that proactive testing can enhance efficacy and reduce toxicity risks. However, translating genetic test findings into treatment recommendations remains a challenge. High-alert cardiovascular drugs have a narrow therapeutic index and pose a high risk of harm if misused. This review focuses on the pharmacogenomics of high-alert cardiovascular drugs, including statins, antiplatelets, adrenergic antagonists, and antiarrhythmics. Understanding the pharmacogenomic factors influencing drug response can aid in tailoring treatment regimens to optimize patient outcomes and minimize adverse reactions in cardiovascular disease management. Keywords: Pharmacogenomics, cardiovascular disease, high alert, drugs, treatment
Publication date: 01/03/2025

https://ijbpas.com/pdf/2025/March/MS_IJBPAS_2025_8805.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.3.8805